Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer.

ABSTRACT: Breast cancer is a persistent threat to women worldwide. A large proportion of breast cancers are dependent on the estrogen receptor α (ERα) for tumor progression. Therefore, targeting ERα with antagonists, such as tamoxifen, or estrogen deprivation by aromatase inhibitors remain standard therapies for ERα + breast cancer. The clinical benefits of monotherapy are often counterbalanced by off-target toxicity and development of resistance. Combinations of more than two drugs might be of great therapeutic value to prevent resistance, and to reduce doses, and hence, decrease toxicity. We mined data from the literature and public repositories to construct a network of potential drug targets for synergistic multidrug combinations. With 9 drugs, we performed a phenotypic combinatorial screen with

SUBMITTER: Hany D 

PROVIDER: S-EPMC10032341 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature